<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), KRAS and BRAF mutations in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> are associated with resistance to anti-epidermal growth factor receptor (anti-EGFR)-based therapies </plain></SENT>
<SENT sid="1" pm="."><plain>However, the correlation between KRAS/BRAF mutation in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and serum has not been well studied </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the degree of concordance of KRAS/BRAF mutations between the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and the matched serum samples in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, serum and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues were collected from 115 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and KRAS/BRAF mutations were examined by nested polymerase chain reaction (PCR) and direct sequencing </plain></SENT>
<SENT sid="3" pm="."><plain>BRAF mutations were present in 3.5% (4/115) of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> tissue samples and 0.87% (1/115) of the serum samples </plain></SENT>
<SENT sid="4" pm="."><plain>In the 4 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with BRAF mutations, identical mutations were not observed in the corresponding serum samples (κ=-0.016) </plain></SENT>
<SENT sid="5" pm="."><plain>KRAS mutations were observed in 32.2% (37/115) of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and 11.3% (13/115) of the serum samples </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 37 tumor cases with KRAS mutations, 9 had identical mutations in the corresponding serum sample, with a concordance rate of 24.3% (9/37) </plain></SENT>
<SENT sid="7" pm="."><plain>Discordance was observed in 32 (27.8%) patients </plain></SENT>
<SENT sid="8" pm="."><plain>The concordance between KRAS mutations in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and KRAS mutations in the matched serums was low (κ=0.231) </plain></SENT>
<SENT sid="9" pm="."><plain>The results of the present study suggest that the possibility of differences in the mutational status of KRAS/BRAF between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and matched serum samples should be considered when patients are selected for anti-EGFR-based therapies </plain></SENT>
</text></document>